Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Obexelimab

Catalog No. T81624Cas No. 1690307-05-1
Alias XmAb5871, AMG729, AMG 729

Obexelimab (XmAb5871) is a bifunctional monoclonal antibody that binds CD19 and FcyRIIb, inhibits B-cells, plasmoblasts, and plasma cells, and may be used in the study of autoimmune diseases such as systemic lupus erythematosus.

Obexelimab

Obexelimab

Purity: 95%
Catalog No. T81624Alias XmAb5871, AMG729, AMG 729Cas No. 1690307-05-1
Obexelimab (XmAb5871) is a bifunctional monoclonal antibody that binds CD19 and FcyRIIb, inhibits B-cells, plasmoblasts, and plasma cells, and may be used in the study of autoimmune diseases such as systemic lupus erythematosus.
Pack SizePriceAvailabilityQuantity
1 mg$293In Stock
5 mg$723In Stock
10 mg$986In Stock
25 mg$1,490In Stock
50 mg$1,970In Stock
Bulk & Custom
Add to Cart
Questions
View More
Select Batch
Concentration:6.29 mg/mL
Purity:95%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Obexelimab (XmAb5871) is a bifunctional monoclonal antibody that binds CD19 and FcyRIIb, inhibits B-cells, plasmoblasts, and plasma cells, and may be used in the study of autoimmune diseases such as systemic lupus erythematosus.
In vitro
Obexelimab induces the expression of genes associated with the apoptotic pathway and promotes apoptosis in B cells. [1]
10 μg/mL Obexelimab, treated for 3 min, inhibited B cell activation and its function by inhibiting BCR-mediated calcium influx and promoting phosphorylation of FcγRIIb. [2]
In vivo
10 mg/kg Obexelimab, injected intraperitoneally twice weekly, suppressed autoimmune responses in immunodeficient mice implanted with peripheral blood mononuclear cells (PBMC) from rheumatoid arthritis (RA) patients. [2]
AliasXmAb5871, AMG729, AMG 729
Chemical Properties
Cas No.1690307-05-1
Storage & Solubility Information
Storagestore at low temperature | store at -20°C | Shipping with blue ice.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy Obexelimab | purchase Obexelimab | Obexelimab cost | order Obexelimab | Obexelimab in vivo | Obexelimab in vitro